SCHEMBL22957681

SCHEMBL22957681

CCNCc1c(F)cccc1OCC1CC1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ RIPK1 Q13546 3/20 0.42
▸ KDM1A O60341 1/20 0.41
▸ MAOA P21397 1/20 0.41
▸ DCPS Q96C86 1/20 0.39
▸ KCNN4 O15554 1/20 0.37
▸ AXL P30530 1/20 0.36
▸ TYRO3 Q06418 1/20 0.36
▸ MERTK Q12866 1/20 0.36
▸ KDM4C Q9H3R0 1/20 0.36
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ HTR2C P28335 5/20 0.35
▸ HTR2B P41595 3/20 0.35
▸ HTR2A P28223 2/20 0.35
▸ HTR7 P34969 1/20 0.34
▸ HTR3A P46098 1/20 0.34
▸ HTR4 Q13639 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22957682 0.86 RIPK1 (0.42) RIPK1KDM1AMAOADCPSKCNN4
SCHEMBL22957904 0.83 RIPK1 (0.47) RIPK1KDM1AMAOADCPSKCNN4
SCHEMBL22957667 0.82 RIPK1 (0.40) RIPK1KDM1AMAOADCPSKCNN4
SCHEMBL22957665 0.82 RIPK1 (0.37) RIPK1KDM1AMAOADCPSKCNN4
SCHEMBL22957830 0.81 AXL (0.46) RIPK1KDM1AMAOAAXLTYRO3
SCHEMBL22957663 0.81 AXL (0.43) RIPK1KDM1AMAOAAXLTYRO3
SCHEMBL22957829 0.78 AXL (0.42) RIPK1KDM1AMAOAAXLTYRO3
SCHEMBL22957648 0.78 AXL (0.42) RIPK1KDM1AMAOADCPSAXL
SCHEMBL20472458 0.78 HTR2C (0.45) RIPK1DCPSKCNN4HTR2CHTR2B
SCHEMBL29786449 0.78 HTR2C (0.45) RIPK1DCPSKCNN4HTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10913738-B2 Aminotriazolopyridines as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2021-02-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10913738-B2 Aminotriazolopyridines as kinase inhibitors RIPK1, RIPK3, RIPK4 RIPK1 1/4885KDM1A 1022/4885MAOA 4183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback